Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2024-09-19 Audit Report / Informat…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Raport z przeglądu biegłego rewidenta
Audit Report / Information Classification · 1% confidence The document is titled "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO SPRAWOZDANIA FINANSOWEGO" (Independent Auditor's Review Report on the Interim Condensed Financial Statements). It explicitly details a review conducted by an auditor (Ernst & Young) on the financial statements for the period ending June 30, 2024, referencing International Accounting Standard 34 (Interim Financial Reporting). This content directly aligns with the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinguishing it from a full Annual Report (10-K) or a simple Earnings Release (ER). The document is the report itself, not an announcement of the report. H1 2024
2024-09-19 Polish
Sprawozdanie z działalności Zarządu - H12024
Interim / Quarterly Report Classification · 1% confidence The document is a 'Sprawozdanie Zarządu z działalności spółki' (Management Report on Company Activity) for the first half of 2024. It contains detailed financial statements, balance sheets, cash flow analysis, and management commentary on financial performance for the period ending June 30, 2024. Since it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2024
2024-09-19 Polish
Sprawozdanie finansowe H12024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'ŚRÓDROCZNE SKRÓCONE SPRAWOZDANIE FINANSOWE' (Interim Condensed Financial Statement) for the 6-month period ending June 30, 2024. It contains detailed financial statements, including the Statement of Comprehensive Income, Statement of Financial Position, and explanatory notes. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2024
2024-09-19 Polish
Oświadczenie KDPW o dokonaniu asymilacji akcji serii C oraz akcji serii E z akcjami Spółki znajdującymi się w obrocie giełdowym - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document text, written in Polish, announces an action by the Management Board (Zarząd) concerning the assimilation (integration/listing) of 100,000 Series C shares and 2,700,000 Series E shares into the shares already traded on the stock exchange, effective September 23, 2024. This action fulfills the condition for introducing these shares to trading on the main market, as previously announced. This directly relates to changes in the company's capital structure and the listing of new shares, which aligns best with the 'Share Issue/Capital Change' category.
2024-09-16 Polish
Dopuszczenie i wprowadzenie akcji zwykłych na okaziciela serii C oraz serii E Spółki do obrotu giełdowego - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document text, written in Polish, announces a resolution by the Management Board of the Warsaw Stock Exchange (GPW) regarding the admission and introduction of Series C and Series E ordinary bearer shares of Celon Pharma S.A. into stock exchange trading. This action directly relates to the listing status and trading of the company's shares on the main market. This is a regulatory announcement concerning the listing/trading of securities, which fits best under the general 'Regulatory Filings' category (RNS) as there is no specific code for 'Stock Listing Admission Announcement'. It is not a report itself, but an official regulatory action notice.
2024-09-13 Polish
Rejestracja akcji serii E Spółki w KDPW - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document is very short (872 characters) and announces a specific corporate action: the registration of 2,700,000 new Series E shares by the National Securities Depository (KDPW) effective August 26, 2024. This action relates directly to a capital increase previously authorized by the General Meeting (mentioned via reference to resolution no. 18). Since the core event is the formalization of newly issued shares and their registration, it falls under the category of changes to the capital structure or share issuance. The most fitting category is 'Share Issue/Capital Change' (SHA). It is not a general announcement of a report (RPA) but a direct notification of a capital event.
2024-08-22 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.